Shots:

• The P-II investigator-initiated proof of concept study (OSIRIS) evaluating the safety, efficacy and tolerability of orismilast (BID for ~16wks.) in patients with HS
• The results showed a clinical improvement for patients who completed the planned 16wks. of treatment, improvements incl. reduction of pain (Global Pain Assessment) and patient-reported quality of life (DLQI). The results were consistent with the results from the P-IIb dose-finding study (IASOS) in psoriasis
• The results will be presented at an upcoming scientific conference. The company continues to advance the development of oral orismilast in HS. UNION & Innovent collaborated in 2021 for the development of orismilast (PDE4 inhibitor) in Mainland China, Hong Kong, Macau, and Taiwan

Ref: PRNewswire | Image: UNION Therapeutics

Related News:- Innovent and UNION Therapeutics Report First Patient Dosing of Orismilast (IBI353) in P-I Study for Atopic Dermatitis and Psoriasis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com